전이성 거세저항성 전립선암 환자의 치료 편집하기 (부분)

== 참고문헌 ==
 1. Halabi S, Small EJ, Vogelzang NJ, et al. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology 2004;64:212-7.

 2. Tewari A, Horninger W, Pelzer AE, et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int 2005;96:1247-52.

 3. Morote J, Orsola A, Planas, et al. Redefining Clinically Significant Castration Levels in Patients With Prostate Cancer Receiving Continuous Androgen Deprivation Therapy. J Urol 2007;178:1290-5.

 4. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration resistant prostate cancer. Cancer Res 2007;67:5033-41.

 5. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008;68:4447-54.

 6. Egan A, Dong Y, Zhang H, et al. Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 2014;40:426-33.

 7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.

 8. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.

 9. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012;368:138-48.

10. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.

11. de Bono JS, Fizazi K, et al. Abiraterone and Increased Survival in Metastatic Prostate Cancer. N Engl J Med 2011;364:1995-2005.

12. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 2013;367:1187-97.

13. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424-33.

14. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010;376:1147-54.

15. Merseburger AS, Hammerer P, Rozet F, et al. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol 2015;33:1079-85.

16. Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, et al. Castration-resistant prostate cancer: AUA Guideline. J Urol 2013190:429-38.

17. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.

18. W. Scott M, Louis R. Kavoussi, et al. Campbell - Walsh Urology 10th ed. Philadelphia: Saunders; 2011; 2921.

19. Jang HS, Koo KC, Cho KS, Chung BH. Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer. Yonsei Med J 2016;57: 1070-8.